Comparing the current results to its competitors, Meiragtx Holdings Plc reported Revenue increase in the 2 quarter 2026 by 8608.59 % year on year. The sales growth was above Meiragtx Holdings Plc's competitors' average revenue growth of 648.11 %, achieved in the same quarter.
Meiragtx Holdings Plc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is highly competitive and characterized by rapidly evolving technologies and a strong focus on intellectual property. Its competitors include large and small biopharmaceutical companies, academic research institutions, government agencies, and both public and private research institutions. These competitors often possess greater financial resources and expertise in areas such as research and development, manufacturing, clinical trials, regulatory approvals, and product marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborations with larger companies.
Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.
Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
Sources:
Meiragtx Holdings Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Meiragtx Holdings Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
